Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VIVUS Inc | VVUS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.79 | 0.00 | 0.00 | 0.00 | 2.79 | 04:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.12 | 4.80 | 2.68 | 55.83% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
VIVUS Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 29.69M | 10.64M | $ -36.95M | -3.47 | -1.13 | 8.17M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 23.20% |
VIVUS News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VVUS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.78 | 2.90 | 2.72 | 2.82 | 37,909 | 0.01 | 0.36% |
| 1 Month | 2.90 | 3.70 | 2.66 | 2.84 | 85,195 | -0.11 | -3.79% |
| 3 Months | 4.09 | 4.38 | 2.66 | 3.46 | 72,098 | -1.30 | -31.78% |
| 6 Months | 3.43 | 4.78 | 2.66 | 3.70 | 85,513 | -0.64 | -18.66% |
| 1 Year | 2.66 | 5.78 | 2.15 | 3.85 | 100,216 | 0.13 | 4.89% |
| 3 Years | 13.80 | 14.70 | 2.15 | 7.98 | 489,437 | -11.01 | -79.78% |
| 5 Years | 31.00 | 34.00 | 2.15 | 15.05 | 846,422 | -28.21 | -91.0% |
VIVUS Description
| VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and Stendra/Spedra, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. The company operates through the single segment of business being Development and commercialization of novel therapeutic products. |
